THERAPY DOSSIER · th-387f68461c90

Porcine pulmonary surfactant

Biologic · Biologic (animal-derived pulmonary surfactant, e.g., poractant/Curosurf); not a discrete ChEMBL small molecule

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Biologic (animal-derived pulmonary surfactant, e.g., poractant/Curosurf); not a discrete ChEMBL small molecule
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00767039 ↗PHASE4terminated

Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With RDS

Respiratory Distress Syndrome

Enrolment: 52 · Results not recorded

NCT03521063 ↗PHASE4unknown

Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia

Respiratory Distress Syndrome

Enrolment: 108 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26073349 ↗2015Reported benefit

The effects of porcine pulmonary surfactant on smoke inhalation injury.

RatOtherSprague-DawleyMalen = 15 rats in three groups of 5Instilled into the airway

Model: Smoke inhalation injury in rats

Surfactant instillation increased arterial oxygen tension, improved oedema status, decreased vascular permeability, improved lung histopathology and reduced the inflammatory response, and increased endogenous surfactant protein A, which correlated negatively with myeloperoxidase activity and interl…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…